Perspective Therapeutics Inc (CATX) PT Lowered to $10 at Truist Securities

Truist Securities analyst Nicole Germino lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $10.00 (from $21.00) while maintaining a Buy rating.

The analyst commented: "Updating our model for 4Q24 results & adjusting commercial launch timelines; CATX ended 4Q24 with ~$227M in cash, cash equivalents and short-term investments, enough to fund clinical efforts into late 2026, as per the Co. Following our discussion with mgmt, we adjusted our model's launch curve timelines for CATX's lead assets to reflect the pace of the dose escalation trials for two clinical programs (neuro-endocrine &melanoma). Given the dosing adjustments to the Phase 1 studies for both clinical programs, our commercial timelines have been pushed out resulting in total product peak 2035E adjusted sales of ~$600M from prior ~$900M. Based on the changes to our model, PT goes to $10 from $21. Maintain Buy."

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
• argenx SE (ARGX) PT Raised to $1,353 at TD Cowen